MOLTALL

Molecularly targeted therapy for T cell acute lymphoblastic leukemia

 Coordinatore VIB 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Belgium [BE]
 Totale costo 1˙384˙632 €
 EC contributo 1˙384˙632 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2007-StG
 Funding Scheme ERC-SG
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-10-01   -   2013-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    VIB

 Organization address address: Rijvisschestraat 120
city: ZWIJNAARDE - GENT
postcode: 9052

contact info
Titolo: Mr.
Nome: Rik
Cognome: Audenaert
Email: send email
Telefono: 3292446611
Fax: 3292446610

BE (ZWIJNAARDE - GENT) hostInstitution 0.00
2    VIB

 Organization address address: Rijvisschestraat 120
city: ZWIJNAARDE - GENT
postcode: 9052

contact info
Titolo: Prof.
Nome: Jan
Cognome: Cools
Email: send email
Telefono: 3216330082
Fax: 3216330084

BE (ZWIJNAARDE - GENT) hostInstitution 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

screens    models    survival    cooperation    leukemic    cell    oncogenes    characterization    molecular    proliferation   

 Obiettivo del progetto (Objective)

'T cell acute lymphoblastic leukemia (T-ALL) is an aggressive T cell malignancy that is most common in children and adolescents. Our current understanding of the molecular genetics of T-ALL indicates that leukemic transformation of thymocytes is caused by the cooperation of mutations that affect proliferation, survival, cell cycle, differentiation and self renewal. Molecular analysis has identified a large number of T-ALL specific oncogenes, but the genetic defects that are implicated in the aberrant proliferation and survival of the leukemic cells remain largely unknown. It is the aim of this project to continue the molecular characterization of T-ALL using genome wide analyses, focused RNAi screens, and drug library screens to identify oncogenes that specifically provide proliferation and survival advantages, as well as other targets for therapy in T-ALL. In addition, we will study the cooperation of these oncogenes with other oncogenic events using in vitro and in vivo mouse models, and use those models for the development and characterization of novel therapeutics. This project will generate novel insights in the molecular pathogenesis of T-ALL and aims at translating this information towards novel targeted therapies.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

BATESON (2012)

Dissecting genotype-phenotype relationships using high-throughput genomics and carefully selected study populations

Read More  

LUMINOS (2014)

Long-wave Ultrafast Multipurpose Intense Nonlinear-Optical Source

Read More  

HEPGAME (2013)

Solving High Energy Physics Equations using Monte Carlo Gaming Techniques

Read More